PTPN2 Modulates STING–STAT3 Signaling and Autophagy in Psoriasis

Study Background and Research Question

Psoriasis is a chronic, immune-mediated skin disorder affecting 2–3% of the global population and is characterized by keratinocyte hyperproliferation, aberrant differentiation, and inflammatory cytokine overproduction. Although biologic therapies have improved clinical outcomes, a substantial proportion of patients experience incomplete or transient responses. This underscores the need to identify new molecular targets that directly modulate keratinocyte-intrinsic signaling pathways, especially those central to inflammation and cellular homeostasis. Persistent activation of signal transducer and activator of transcription 3 (STAT3) is a hallmark of psoriatic lesions, driving keratinocyte proliferation and resistance to apoptosis. However, the upstream mechanisms regulating STAT3 activity in psoriasis remain poorly defined. The present study addresses this gap by investigating the role of protein tyrosine phosphatase nonreceptor type 2 (PTPN2) in the regulation of the STING–STAT3 axis and its impact on autophagy in psoriasis models (reference study).

Key Innovation from the Reference Study

The central innovation of this research lies in elucidating a mechanistic link between PTPN2, the STING–STAT3 signaling pathway, and the restoration of autophagy in keratinocytes. Prior work recognized PTPN2 as a negative regulator of inflammatory signaling but did not define its precise role in psoriasis. This study demonstrates, through both in vitro and in vivo models, that PTPN2 directly interacts with and dephosphorylates STING, leading to downstream suppression of STAT3 activation. The authors show that PTPN2 overexpression curbs keratinocyte proliferation, induces apoptosis, and restores autophagy, all while attenuating proinflammatory cytokine secretion. These effects are reversed by STING activation but restored upon STAT3 inhibition, establishing the STING–STAT3 axis as a critical mediator of PTPN2 function in psoriasis.

Methods and Experimental Design Insights

The research team employed a combination of cellular and animal models to dissect the signaling mechanisms underlying psoriatic pathology. Key experimental approaches included:

• Assessment of PTPN2 expression in psoriatic and control tissues using immunofluorescence and Western blotting.
• Overexpression and catalytic-dead mutant constructs to dissect the phosphatase activity of PTPN2.
• Co-immunoprecipitation assays to confirm direct interaction and dephosphorylation of STING by PTPN2.
• Evaluation of keratinocyte proliferation, apoptosis, and autophagy through established cell biology and molecular assays.
• Use of imiquimod-induced mouse models to validate in vivo relevance and the therapeutic effect of PTPN2 modulation.
• Pharmacological manipulation using STING agonists and STAT3 inhibitors to probe pathway specificity.

This multifaceted design allowed the authors to link molecular, cellular, and tissue-level changes with modulation of the STING–STAT3 pathway in both experimental systems.

Core Findings and Why They Matter

The study's most impactful findings include:

• Downregulation of PTPN2 in Psoriatic Lesions: Both human and mouse psoriatic tissues exhibited significantly reduced PTPN2 expression, implicating this phosphatase in disease progression.
• PTPN2 Directly Regulates STING Phosphorylation: Overexpression of wild-type PTPN2, but not a catalytic-dead mutant, reduced STING phosphorylation. This effect was necessary for downstream STAT3 inhibition.
• Suppression of STAT3 Activation: Elevated STAT3 phosphorylation, a driver of keratinocyte hyperproliferation and reduced apoptosis, was reversed by PTPN2 overexpression.
• Restoration of Autophagy and Induction of Apoptosis: PTPN2 promoted both autophagy and apoptosis in keratinocytes, counteracting the hyperproliferative state typical of psoriasis.
• Reduction of Proinflammatory Cytokine Secretion: Levels of TNF-α, IL-23A, and IL-17A were significantly decreased following PTPN2 overexpression, dampening the pathogenic inflammatory cascade.
• Interplay with STING and STAT3: Activation of STING attenuated the beneficial effects of PTPN2, while STAT3 inhibition restored them—defining a functional STING–STAT3 signaling axis in keratinocytes.
• In Vivo Efficacy: Overexpression of PTPN2 ameliorated psoriatic pathology in imiquimod-induced mouse models, with additional benefit observed upon co-administration of the autophagy inducer rapamycin (reference study).

Collectively, these results clarify that PTPN2 is a negative regulator of the STING–STAT3 axis, and restoration of its function suppresses psoriasis-like phenotypes by rebalancing keratinocyte homeostasis.

Comparison with Existing Internal Articles

Recent internal resources have explored the nuances of STAT3 inhibition in cancer biology and immune signaling. For example, the article "PTPN2 Modulates STING–STAT3 Axis and Autophagy in Psoriasis" provides mechanistic context, confirming that PTPN2 acts as a negative regulator of STAT3 signaling and autophagy in keratinocytes, closely paralleling the findings of the reference study. In the oncology domain, resources such as "Stattic and the STAT3 Axis: Redefining Translational Strategies" and "Stattic: STAT3 Inhibitor Workflows for Cancer Biology" detail how selective STAT3 inhibitors like Stattic enable precise dissection of STAT3-dependent pathways, supporting workflows for apoptosis induction in cancer cells and advancing radiosensitization strategies. While these articles focus primarily on cancer biology, the current psoriasis study strengthens the rationale for targeting STAT3 in non-neoplastic, immune-mediated disorders, bridging mechanistic insight across disease domains.

Limitations and Transferability

Despite the robust mechanistic evidence, several limitations warrant consideration. First, while the imiquimod-induced mouse model recapitulates many features of human psoriasis, it cannot fully capture the complexity and chronicity of the human disease. Second, overexpression systems may not perfectly mirror physiological regulation of PTPN2, and off-target effects of pharmacological modulators (such as STING agonists or STAT3 inhibitors) cannot be excluded. Third, the translational applicability of targeting PTPN2 in human patients will require further validation, including assessment of safety, specificity, and long-term efficacy. Finally, while the study demonstrates that STAT3 inhibition can restore the protective benefits of PTPN2, clinical implementation of STAT3 inhibitors in inflammatory skin disease remains in early stages.

Protocol Parameters

• Keratinocyte culture and transfection: Use standard conditions for HaCaT or primary human keratinocytes; transfect with PTPN2 overexpression or control vectors using lipofection or electroporation protocols.
• Imiquimod-induced psoriasis model: Apply 5% imiquimod cream daily to mouse dorsal skin for 5–7 days to induce psoriatic phenotype; assess tissue changes histologically and via biomarker analysis.
• Pharmacological modulation: For pathway interrogation, apply STING agonists or STAT3 inhibitors at concentrations validated in pilot studies; confirm pathway engagement by immunoblotting for phosphorylated STAT3 and STING.
• Autophagy and apoptosis assays: Quantify autophagic activity with LC3-II immunoblotting and/or fluorescent autophagosome markers; assess apoptosis via TUNEL staining or caspase-3 activity assays.
• For research involving small-molecule STAT3 inhibitors (such as Stattic), consult the product information for recommended concentrations and solvent compatibility.

Research Support Resources

To experimentally model STAT3 pathway inhibition in keratinocytes or other cell types, researchers can employ selective STAT3 inhibitors such as Stattic (SKU A2224), a potent small-molecule agent that prevents STAT3 dimerization and nuclear translocation. Stattic is widely applied in cancer biology, apoptosis induction, and mechanistic dissection of STAT3-dependent processes, and its use may be extended to immune-mediated skin disease models as suggested by the current mechanistic findings (internal resource). For detailed protocols, storage, and solvent compatibility, refer to the APExBIO technical documentation. Integrating such targeted tools can facilitate reproducible investigation of STAT3 signaling in both neoplastic and inflammatory disease settings.